Literature DB >> 22104312

Local recurrence as immunoglobulin G4 (IgG4)-related disease 10 years after radiotherapy to ocular adnexal extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.

Toshihiko Matsuo1, Kouichi Ichimura, Tadashi Yoshino.   

Abstract

In 2000, a 48-year-old woman developed a left orbital mass with lacrimal gland involvement and then, in 2003, a right orbital mass with lacrimal gland involvement, both of which were diagnosed as extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). She underwent 30 Gy external beam radiation to bilateral orbital lesions. The lymphoma cells in both lesions did not share the same clonality, as shown by amplification by polymerase chain reaction of the immunoglobulin heavy chain gene. Immunoglobulin light chain analysis by immunohistochemistry and messenger RNA in situ hybridization showed λ chain monotype in the left orbital lesion but κ chain monotype in the right orbital lesion. She developed recurrent left orbital mass with high uptake on fluorodeoxyglucose positron emission tomography fused with computed tomography in 2010, and excisional biopsy disclosed the formation of follicles and infiltration with immunoglobulin G4 (IgG4)-positive plasma cells mainly in interfollicular areas. The immunoglobulin light chain analysis showed the λ chain and κ chain bitype. With the immunohistopathological diagnosis of IgG4-related disease, the serum IgG4 level was found to show elevation at 376 mg/dL, and the patient chose observation. This is the first reported case of development of IgG4-related disease after bilataral orbital MALT lymphoma with external beam radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22104312     DOI: 10.3960/jslrt.51.125

Source DB:  PubMed          Journal:  J Clin Exp Hematop        ISSN: 1346-4280


  7 in total

Review 1.  Diagnostic criteria for IgG4-related ophthalmic disease.

Authors:  Hiroshi Goto; Masayuki Takahira; Masahiro Takahira; Atsushi Azumi
Journal:  Jpn J Ophthalmol       Date:  2014-11-14       Impact factor: 2.447

2.  Spectrum of B-cell neoplasms associated with immunoglobulin G4-related disease.

Authors:  Ryan C W Ho; Thomas S Y Chan; Rex Au-Yeung; Karen H K Tang; Yu-Yan Hwang; Eric Tse; Yok-Lam Kwong
Journal:  Ann Hematol       Date:  2021-11-12       Impact factor: 3.673

3.  Development of IgG4-related disease 10 years after chemotherapy for diffuse large B cell lymphoma and longstanding bronchial asthma.

Authors:  Takeki Mitsui; Akihiko Yokohama; Hiromi Koiso; Takuma Ishizaki; Hideki Uchiumi; Takayuki Saitoh; Hiroshi Handa; Junko Hirato; Masamitsu Karasawa; Hirokazu Murakami; Masaru Kojima; Yoshihisa Nojima; Norifumi Tsukamoto
Journal:  Int J Hematol       Date:  2013-05-12       Impact factor: 2.490

4.  Occurrence of anaplastic large cell lymphoma following IgG4-related autoimmune pancreatitis and cholecystitis and diffuse large B-cell lymphoma.

Authors:  Mitsuaki Ishida; Keiko Hodohara; Keiko Yoshida; Akiko Kagotani; Muneo Iwai; Miyuki Yoshii; Hiroko Okuno; Akiko Horinouchi; Ryota Nakanishi; Ayumi Harada; Takashi Yoshida; Hidetoshi Okabe
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

5.  Immunoglobulin G4-related disease (IgG4-RD) in the orbit: mucosa-associated lymphoid tissue (MALT)-type lymphomas.

Authors:  Krzysztof Oleś; Jacek Składzień; Wojciech Szczepański; Krzysztof Okoń; Joanna Leszczyńska; Emilia Bojanowska; Krzysztof Bartuś; Joanna Mika
Journal:  Med Sci Monit       Date:  2015-04-10

6.  Follow-up with serum IgG4-monitoring in 8 patients with IgG4-related disease diagnosed by a lacrimal gland mass.

Authors:  Toshihiko Matsuo; Takehiro Tanaka; Yasuharu Sato; Hitomi Kataoka; Mayu Uka; Daisuke Ennishi; Tomofumi Yano
Journal:  J Clin Exp Hematop       Date:  2021

Review 7.  Diffuse Large B-Cell Lymphoma 18 Years After Bilateral Lacrimal Gland IgG4-Related Disease: Case Report and Literature Review.

Authors:  Toshihiko Matsuo; Takehiro Tanaka; Kenji Notohara; Kazuya Okada
Journal:  J Investig Med High Impact Case Rep       Date:  2022 Jan-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.